Risk factors for NRM by univariate and multivariate analyses
| . | Univariate analysis . | Multivariate analysis* . | Multivariate analysis* . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| M2BPGi | ||||||
| COI < 1.5 | 1 | Ref | 1 | Ref | 1 | Ref |
| COI ≥ 1.5 | 11.27 (2.61-48.67) | 0.001 | 9.20 (1.87-45.26) | 0.006 | 8.52 (1.67-43.51) | 0.010 |
| Thrombocytopenia† | ||||||
| No | 1 | Ref | 1 | Ref | ||
| Yes | 3.40 (1.25-9.26) | 0.017 | 3.60 (1.03-12.63) | 0.045 | ||
| NIH global severity score‡ | ||||||
| 0/1/2 | 1 | Ref | 1 | Ref | ||
| 3 | 13.8 (4.50-42.06) | <0.001 | 4.46 (1.44-13.84) | 0.010 | ||
| Liver severity score§ | ||||||
| 0/1/2 | 1 | Ref | 1 | Ref | ||
| 3 | 12.2 (3.40-43.53) | <0.001 | 9.24 (2.06-41.40) | 0.004 | ||
| HCT-CI | ||||||
| 0-1 | 1 | Ref | 1 | Ref | 1 | Ref |
| ≥2 | 3.68 (1.25-10.89) | 0.018 | 3.17 (1.16-8.69) | 0.025 | 3.48 (1.12-10.87) | 0.032 |
| . | Univariate analysis . | Multivariate analysis* . | Multivariate analysis* . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| M2BPGi | ||||||
| COI < 1.5 | 1 | Ref | 1 | Ref | 1 | Ref |
| COI ≥ 1.5 | 11.27 (2.61-48.67) | 0.001 | 9.20 (1.87-45.26) | 0.006 | 8.52 (1.67-43.51) | 0.010 |
| Thrombocytopenia† | ||||||
| No | 1 | Ref | 1 | Ref | ||
| Yes | 3.40 (1.25-9.26) | 0.017 | 3.60 (1.03-12.63) | 0.045 | ||
| NIH global severity score‡ | ||||||
| 0/1/2 | 1 | Ref | 1 | Ref | ||
| 3 | 13.8 (4.50-42.06) | <0.001 | 4.46 (1.44-13.84) | 0.010 | ||
| Liver severity score§ | ||||||
| 0/1/2 | 1 | Ref | 1 | Ref | ||
| 3 | 12.2 (3.40-43.53) | <0.001 | 9.24 (2.06-41.40) | 0.004 | ||
| HCT-CI | ||||||
| 0-1 | 1 | Ref | 1 | Ref | 1 | Ref |
| ≥2 | 3.68 (1.25-10.89) | 0.018 | 3.17 (1.16-8.69) | 0.025 | 3.48 (1.12-10.87) | 0.032 |
Because the NIH global severity score and liver severity score were highly correlated, each covariate was subjected to a separate multivariate analysis.
Ref, reference.
Other variables that were included in the multivariate analysis were age (<50 vs ≥50 years), sex (female to male vs others), HCT-CI (0-1 vs ≥2), HLA compatibility (match vs mismatch), and use of ATG/alemtuzumab.
Thrombocytopenia was defined as <100 000 platelets per microliter at sample collection.
NIH global severity score was evaluated at sample collection.
Liver severity score was evaluated at sample collection.